Short Interest in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Declines By 17.0%

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 5,030,000 shares, a decrease of 17.0% from the February 28th total of 6,060,000 shares. Based on an average trading volume of 555,900 shares, the days-to-cover ratio is currently 9.0 days. Approximately 10.0% of the company’s shares are short sold.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday.

Supernus Pharmaceuticals Stock Performance

SUPN stock traded up $0.62 during midday trading on Wednesday, reaching $32.30. The stock had a trading volume of 71,653 shares, compared to its average volume of 477,740. The firm has a fifty day simple moving average of $34.91 and a two-hundred day simple moving average of $35.06. The stock has a market cap of $1.80 billion, a PE ratio of 30.19 and a beta of 0.84. Supernus Pharmaceuticals has a 52-week low of $25.53 and a 52-week high of $40.28.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Barclays PLC lifted its position in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after buying an additional 51,005 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 2,121 shares during the period. Empowered Funds LLC purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth about $1,498,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.